A multicultural group practicing yoga together in a bright studio

Henry Meds vs WellMedr: GLP-1 Comparison 2026

Henry Meds vs WellMedr: pricing, medication type, clinical support, and which budget-conscious GLP-1 patient each program fits. Both programs’ prices verified June 2026 or later; each price carries its own date in the table below.

By RangeYourselfUpdated August 10, 20264 min read

Quick answer

Henry Meds typically wins on sticker price for compounded GLP-1. Choose Henry Meds if you're price-first; choose WellMedr if you want brand-name (FDA-approved) access.

Side-by-side comparison

Feature	Henry Meds	WellMedr
Best for	Simple compounded program with broad availability	Microdose-GLP-1 blend plans (tirzepatide combined with NAD+ or B12/MIC in one $199/mo subscription) and flat-priced prescription NAD+ ($99/mo advertised, same price every dose)
Medication type	Compounded semaglutide and tirzepatide	Compounded semaglutide and tirzepatide (injectable and oral), a distinct microdose GLP-1 blend line (tirzepatide with NAD+/B12 or B12/methionine/inositol), brand Ozempic and Zepbound listings, plus NAD+, TRT/enclomiphene, ED and hair-loss lines on one telehealth menu
Pricing model	Flat monthly, dose-banded	Cash-pay recurring subscription enrolled at purchase; main GLP-1 pricing is funnel-gated (Shopify catalog exposes $0.00 placeholder variants; no single defensible recurring price, Oak/LIV Body/telos mechanism); the microdose blend line advertises $199/mo on its own page and a '50% off your first month' promo runs on compounded GLP-1/GIP
Semaglutide price	From $179/mo	Compounded, injectable and oral offered; recurring rate not published on the public site (funnel-gated), confirm at enrollment
Tirzepatide price	From $179/mo	Compounded, injectable and oral offered; recurring rate not published (funnel-gated). Microdose blend plans containing tirzepatide (with NAD+/B12, or B12/methionine/inositol) are page-priced at $199/mo (verified 2026-08-10), confirm the exact plan at enrollment
Key watchout	Limited brand-name path if you later want Wegovy/Zepbound	WellMedr's own pages contradict each other on FDA status: a site-wide footer correctly states its compounded medications 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality,' while its FAQ answers 'Are these medications FDA approved? Yes.' and its microdosing page calls them 'FDA-approved compounds' and claims 'ZERO side effects' for most members, claims we do not repeat as fact. No dispensing pharmacy is named, no 503A/503B status is stated, no state list is published, and the main GLP-1 recurring price is only shown inside the intake funnel, confirm the real price, the pharmacy, and your state's eligibility before paying.
Price checked	Checked by a person June 30, 2026 · an automated check re-read it September 3, 2026	Checked by a person August 10, 2026

When to choose Henry Meds

You want a well-known compounded program with predictable pricing
You value broad state availability and a fast intake
You're committed to compounded and don't need a brand-name option
You want a smooth user experience over the lowest possible price

Check current Henry Meds pricing →

When to choose WellMedr

You want a microdosed GLP-1 plan sold as a flat $199/mo blend subscription (tirzepatide with NAD+/B12 or B12/MIC) rather than a standard-dose program
You want prescription NAD+ at a flat advertised $99/mo, same price every dose per WellMedr's own page (not the registry's cheapest: Enhance MD's sublingual is $84/mo and bmiMD's injection $89/mo)
You're comfortable confirming the real recurring GLP-1 price inside the intake flow, WellMedr publishes no standing GLP-1 rate on its public site
You've read the FDA-status watchout above and are comfortable with a program whose own pages are inconsistent about it

Check current WellMedr pricing →

Full reviews

Frequently asked questions

Is Henry Meds cheaper than WellMedr?

Neither Henry Meds nor WellMedr is uniformly cheaper, both publish dose-banded and formulation-banded pricing that depends on the exact product, dose, and any insurance pathway. Compare the specific tier you'd be on at each before deciding.

Which is better for semaglutide or tirzepatide, Henry Meds or WellMedr?

Both Henry Meds and WellMedr prescribe semaglutide and tirzepatide where appropriate. Choose based on how each program handles your target medication, not just the entry price.

Are Henry Meds and WellMedr compounded or brand-name?

Henry Meds offers compounded semaglutide and tirzepatide. WellMedr offers compounded semaglutide and tirzepatide (injectable and oral), a distinct microdose glp-1 blend line (tirzepatide with nad+/b12 or b12/methionine/inositol), brand ozempic and zepbound listings, plus nad+, trt/enclomiphene, ed and hair-loss lines on one telehealth menu. If you specifically want brand-name Wegovy or Zepbound, lean toward whichever explicitly supports brand access; if compounded is fine, both can typically meet that need.

Can I switch from Henry Meds to WellMedr?

Yes, switching between Henry Meds and WellMedr is straightforward in most states. You typically finish your current month, complete a new intake with the other provider, and they handle the prescription. Watch for overlap on auto-renewal billing and confirm any dose-tier or formulation differences with the new clinician before your next shipment.

Compare Henry Meds and WellMedr to other programs

Alert me when this gets cheaper

These prices move. Get one email when we publish a verified price drop, the programs on this list included. No spam. Unsubscribe any time.

Related guides

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Pricing reflects publicly listed entry tiers, verified on the dates shown in the table above, and may change. Numbers like $179/mo and Compounded, injectable and oral offered; recurring rate not published on the public site (funnel-gated), confirm at enrollment are starting tiers, not your guaranteed long-term cost.